头颈肿瘤游离皮瓣术后住院利用新指标HUM研究
回顾性分析626例头颈微血管游离皮瓣病例,提出整合原住院时长与再入院时长的住院利用指标HUM。HUM中位数0.18,60天再入院率34.3%;术后并发症与HUM升高相关,高HUM与术后1年生存更差相关。
要点
- HUM整合原住院与再入院时长,比单一住院时长更全面反映医疗利用。
- 术后并发症与HUM升高独立相关,私立保险与较低HUM及较短住院相关。
- 高HUM与术后1年生存更差相关,而原住院时长无此关联。
核心结论
- HUM较原住院时长和再入院率更全面评估医疗利用,可能作为患者生活质量与医疗费用的实用替代指标。
研究设计与样本
- 回顾性分析2019年8月至2024年5月共626例头颈微血管游离皮瓣病例,来自匹兹堡大学医学中心。
- 主要结局为HUM,按总住院时长除以60天计算,以中位数分组定义高HUM(>0.18)。
主要发现
- 626例患者平均年龄62.7±11.9岁,男性68.2%,白人92.0%,III/IV期肿瘤74.1%,公共保险63.1%。
- 原住院时长中位数9天(IQR 7-14),HUM中位数0.18(IQR 0.13-0.28),60天再入院率34.3%。
临床怎么用
- 临床可考虑用HUM替代单一住院时长,综合评估头颈游离皮瓣术后医疗利用与预后。
- 术后并发症和重返ICU是HUM升高的可干预因素,应加强围手术期管理。
局限性
- 单中心回顾性研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The primary length of stay (PLOS) metric fails to capture added time, costs, and reduced patient quality of life (QOL) associated with readmissions. To address these limitations, we propose a novel metric, the hospitalization utilization metric (HUM), which integrates PLOS and readmission LOS (RLOS). STUDY DESIGN: Retrospective review of 626 head and neck microvascular free flap (MVFF) cases from August 2019 to May 2024. SETTING: University of Pittsburgh Medical Center. METHODS: Main outcome measure was HUM, calculated as total length of stay (TLOS) (TLOS = [PLOS + RLOS]/60 days). High HUM, determined by median split, was >0.18. RESULTS: Our 626-patient cohort averaged 62.7 ± 11.9 years old. The majority of patients were male (68.2%), white (92.0%), with advanced tumors (III/IV: 74.1%), and public insurance (63.1%). The median (interquartile range [IQR]) PLOS was 9 (7-14), median (IQR) HUM was 0.18 (0.13-0.28), and the rate of 60-day re-presentation/readmission was 34.3%. Multivariable logistic regression identified postoperative complications (β: .08, P < .001; β: 4.44, P < .001, respectively) and private insurance (β: -.04, P < .02; -2.71, P < .01) as predictive factors associated with both higher HUM and PLOS (>9 days), respectively. Return to intensive care unit (ICU) (β: .08, P < .003) and duration of surgery (β: .005, P < .048) were independently associated with higher HUM, although both effect sizes are relatively small. Kaplan-Meier survival curves revealed that higher HUM (P = .030) but not PLOS (P = .098) was associated with worse survival 1 year postoperatively. CONCLUSION: HUM provides a comprehensive assessment of healthcare utilization compared to PLOS and re-presentation alone and may be a practical surrogate for patient QOL and healthcare costs.
引用
- Abdul-Rahman NH, Tang A, Balogun Z, et al. Hospitalization Utilization Metric After Major Oncologic Head and Neck Surgery With Microvascular Free Flap. Otolaryngol Head Neck Surg. 2026. PMID: 42606114. doi:10.1002/ohn.70377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。